PRA Health Sciences Opens New Bioanalytical Laboratory in the Netherlands
27 October 2015 - 12:00AM
PRA Health Sciences (PRA) (NASDAQ:PRAH) is pleased to announce the
opening of its brand new, state-of-the-art Bioanalytical Laboratory
in Assen, the Netherlands. The 33,000 square foot facility provides
25 percent more space than PRA’s previous lab, includes investments
in the newest small and large molecule equipment, and allows for
optimal bioanalytical process efficiencies. The new laboratory is
also located close to PRA’s Phase I clinics in Groningen and
Zuidlaren, providing easy access and analysis of the most
time-critical samples and execution of adaptive trials.
“We are proud to offer our clients industry-leading, high
quality, high science laboratory services in this new and
innovative environment,” said Peter Ketelaar, PRA Vice President of
Global Bioanalytical Laboratory Services. “The new facility is a
testament to PRA’s commitment to excellence and our passion to
advance clinical development.”
PRA bioanalytical laboratories have 30+ years of experience in
providing bioanalytical services in support of clinical and
pre-clinical trials for both small and large molecules. Industry
leading experts with a depth of scientific and regulatory knowledge
and experience manage and support PRA’s laboratory services,
contributing to successful development of new medicines.
“Our technology investments and innovative services operations
are what set PRA apart in the industry,” said PRA CEO Colin
Shannon. “We take enormous pride in the expertise we bring to the
table that enables us to excel at clinical research and deliver
quality results for our clients and patients.”
PRA operates GLP-compliant (Good Laboratory Practice) and fully
harmonized bioanalytical laboratories in the Netherlands and the
Unites States (Lenexa, Kansas). Both are strategically located near
PRA’s clinical research units to enable close collaboration and
faster drug development decision making.
ABOUT PRA HEALTH SCIENCES
At PRA Health Sciences, providing innovative solutions for our
clients is what we do. Side-by-side with our clients, we strive to
move drug discovery forward, helping them to develop life-saving
and life-improving drugs. PRA has more than 11,000 employees
working in 80+ countries providing comprehensive clinical
development services across all phases. From full service clinical
development to the pioneering Embedded Solutions™ model, PRA
provides a broad spectrum of solutions that meet the demands of a
diverse marketplace. PRA has worked on 100+ marketed drugs across
several therapeutic areas and conducted the pivotal or supportive
trials that led to FDA and/or international regulatory approval of
50+ such drugs.
INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications
EMAIL: rogerschristine@prahs.com PHONE: +1 919.786.8463
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Jun 2024 to Jul 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Jul 2023 to Jul 2024